Hypertension and coronary artery disease

RC, a 22-year-old woman, presents to your clinic requesting information on contraception. You begin to take a history and determine that the patient is currently sexually active and is not using any method of birth control. Her past medical history is significant only for acne, and she takes no medications except occasional ibuprofen for menstrual cramps. On further questioning, you discover that she has a positive family history for hypertension and coronary artery disease. As you begin to discuss various contraceptive options with the patient, it is clear that she has a preference for an oral contraceptive agent. 

The complexity of the heart failure syndrome necessitates a comprehensive approach to management that includes accurate diagnosis, identification and treatment of risk factors (e.g., diabetes, hypertension, and coronary artery disease), elimination or minimization of precipitating factors such as NSAlDs, and appropriate pharmacologic and nonpharmacologic therapy. 

While asymptomatic hyperuricemia is not generally treated, some clinicians have begun recommending treatment to reduce the risk of coronary artery disease. Hyperuricemia is associated with both hypertension and coronary artery disease, and patients with elevated uric acid levels and hypertension are at increased risk of cardiovascular morbidity and mortality. 

Thomas, C. B., and H. B. Cohen Familial occurence of hypertension and coronary artery disease with observations concerning obesity and diabetes. Ann. intern. Med. 42, 90 (1955). 

Serum lipids, hypertension and coronary artery disease. 

Contraindications to these agents include hypertension, tachyarrhythmias, coronary artery disease, myocardial infarction, cor pulmonale, hyperthyroidism, renal failure, and narrow-angle glaucoma. 

An SPE cartridge can be used multiple times, especially after the samples are pretreated with protein precipitation. Bourgogne et al. (2005) quantitated talinolol, a p -adrenoceptor antagonist used to treat arterial hypertension and coronary heart disease, in human plasma. The sample was first precipitated with perchloric acid and the supernatant was injected directly. An Xterra MS analytical column (50 x 4.6 mm, 3.5 [m, Waters) with a C18 recolumn filter (4x2 mm, 3.5 /.mi, Phenomenex) and a C8 EC cartridge were chosen. The cycle time was 4.8 min and linear range was 2.5 to 200 ng/mL. Protein precipitation allowed the SPE cartridge to be used for more than 90 injections. 

Almost 40% of hypertensive patients have LVH which, after age, is the strongest predictor of cardiovascular disease, such as congestive heart failure (CHF), stroke, and coronary artery disease (CAD). Cardiovascular events occur in relation to left ventricular mass. Blood pressure reduction causes LVH regression, and therefore decreases the risk of all-cause, cardiovascular, and CAD mortality. ARBs have been shown to reduce LVH in a number of trials, including losartan in the LIFE [8] and irbesartan in the SILVHIA study [9]. 

Diseases of the heart and circulatory system, cardiovascular diseases, have long been the leading cause of mortality in Europe and North America, and total cholesterol and low-density lipoprotein (LDL) cholesterol are the two most important risk factors for coronary heart disease. Decreased arterial compliance of the arteries is thought to contribute to systolic hypertension and coronary artery insufficiency. A number of nutraceuticals have been used for long-term prevention or symptom reduction in cardiovascular diseases, notably soy products, tea flavonoids, octacosanol, n-3-polyunsaturated fatty acids (PUFAs), and, to a lesser extent, melatonin, Pycnogenol, resveratrol, coenzyme QIO, lycopene, and DHEA. 

Ciclosporin-induced encephalopathy was precipitated by diltiazem in a 76-year-old white woman with corticosteroid-resistant aplastic anemia and thrombocjdope-nia, type 2 diabetes, and coronary artery disease, who was taking diltiazem for hypertension (28). She became comatose after 13 days of therapy with ciclosporin, and clinical examination and electroencephalography showed diffuse encephalopathy of moderate severity. Ciclosporin was withdrawn and she regained consciousness after 36 hours. 

The S4 diastolic sound is a dull, low-pitched postsystolic atrial gallop (rapid blood flow) usually due to reduced ventricular compliance. It is best heard at the apex in the left lateral position. Like S3, it occurs with reduced ventricular compliance and is present in conditions such as aortic stenosis, hypertension, hypertrophic cardiomyopathies, and coronary artery disease. It is less specific for congestive heart failure than S3. 

Patients in stage A do not have structural heart disease or symptoms but are at high risk for developing heart failure because of the presence of risk factors. The emphasis here is on identification and modification of these risk factors to prevent the development of structural heart disease and subsequent heart failure. Commonly encountered risk factors include hypertension, diabetes, and coronary artery disease. Although each of these disorders individually increases risk, they frequently coexist in many patients and act synergisticaUy to foster the development of heart failure. Effective control of blood pressure reduces the risk... 

The rationale underlying the treatment of chronic HTN concerns its association with atherosclerosis and the increased risk of stroke, heart failure, renal diseases, peripheral vascular disease, and coronary artery disease. Except in severe HTN, there is no rash to start drug Rx prior to lifestyle changes because the goals are long term. Factors in hypertension include decreases in vagal tone, increases in sympathetic tone, increased renin-angiotensin activity, and water retention. 

The above findings confirm that exposure to PSCI RCAs by airborne dispersion or by contamination in solution produce abrupt and marked increases in SBP and DBP, with resolution within about 0.5 h of the start of exposure. The magnitude and duration of the changes can be tolerated without significant medical hazards in healthy individuals. However, as with other stressful situations, some susceptible individuals may be at increased risk from the induced transient hypertensive episode this will include those with essential hypertension, established myocardial infarction and coronary artery disease, cardiac arrhythmias and arterial aneurysms (Ballantyne, 1977a, 1987 Ballantyne and Salem, 2004). 

LEAD patients often suffer from comorbidities, including hypertension, diabetes mellitus, dyslipidemia, and coronary artery disease. In addition, the sedentary lifestyle fostered by claudication accelerates the deterioration of cardiorespiratory and muscular functions, and leads to a decline in the overall health and quality of life for the LEAD patient (4). Thus, treatment for intermittent claudication should include lifestyle changes for positive modification of the traditional cardiovascular disease risk factors. 

There can be a number of underlying causes of CHE. The most prevalent is the lack of oxygenated blood reaching the heart muscle itself because of coronary artery disease with myocardial infarction (111). Hypertension and valvular disease can contribute to CHE as well, but to a lesser extent in terms of principal causes for the disease. 

The antipsychotics are contraindicated in patients with known hypersensitivity to the drug s, in comatose patients, and in those who are severely depressed, have bone marrow depression, blood dysera ias, Parkinson s disease (haloperidol), liver impairment, coronary artery disease, or severe hypotension or hypertension. 

The decongestants are contraindicated in patients with known hypersensitivity, hypertension, and severe coronary artery disease These drugs are also contraindicated in patients taking monoamine oxidase inhibitors (MAOIs). Naphazoline is contraindicated in patients with glaucoma. 

---